Cargando…

CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease

With the rising prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) now affects 20–25% of the global population. NAFLD, a progressive condition associated with oxidative stress, can result in cirrhosis and liver cancer in 10% and 3% of patients suffering NAFLD, respectively. Therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, James, Arest, Sandra, Olszowy, Bartlomiej, Gordon, John, Barrero, Carlos A., Perez-Leal, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375998/ https://www.ncbi.nlm.nih.gov/pubmed/37507903 http://dx.doi.org/10.3390/antiox12071363

Ejemplares similares

Identification of Inhibitors of Tubulin Polymerization Using a CRISPR-Edited Cell Line with Endogenous Fluorescent Tagging of β-Tubulin and Histone H1
por: Khachatryan, Harutyun, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Multiplex Gene Tagging with CRISPR-Cas9 for Live-Cell Microscopy and Application to Study the Role of SARS-CoV-2 Proteins in Autophagy, Mitochondrial Dynamics, and Cell Growth
por: Perez-Leal, Oscar, et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
por: Hariani, Gunjan D, et al.
Publicado: (2014)

Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
por: Hariani, Gunjan D, et al.
Publicado: (2014)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
por: Leal, Ticiana A., et al.
Publicado: (2022)

A newly discovered Bordetella species carries a transcriptionally active CRISPR-Cas with a small Cas9 endonuclease
por: Ivanov, Yury V., et al.
Publicado: (2015)

CRISPR–Cas system to discover host-virus interactions in Flaviviridae
por: Ramezannia, Zahra, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

What is CRISPR/Cas9?
por: Redman, Melody, et al.
Publicado: (2016)

Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022)

The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
por: Qiao, Huanhuan, et al.
Publicado: (2021)

The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer
por: Zhang, Jiayu, et al.
Publicado: (2018)

RNA-dependent RNA targeting by CRISPR-Cas9
por: Strutt, Steven C, et al.
Publicado: (2018)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

CRISPR/Cas9 in Gastrointestinal Malignancies
por: Jefremow, André, et al.
Publicado: (2021)

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021)

Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers
por: Flores Monar, Gabriela Vanessa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5bgajb0pqr2uqe3e4914n9idd6